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ABSTRACT	
Introduction:	
Hepatitis	C	Virus	(HCV)	Infection	is	the	most	common	blood-borne	infection	in	the	world	with	a	
global	prevalence	of	~3%.	It	also	represents	an	underestimated	and	under-recognized	viral	
infection	because	it	is	asymptomatic	during	the	initial	period	of	infection,	which	tends	to	span	
several	decades.	However,	after	establishing	itself	as	a	chronic	state,	HCV	infection	often	leads	
to	severe	debilitating	liver	conditions	such	as	cirrhosis,	hepatocellular	carcinoma	to	name	a	few	
resulting	in	poor	quality	of	life,	increased	healthcare	costs	and	mortality.	Several	earlier	studies	
have	examined	risk	factors	associated	with	HCV.	However,	a	comprehensive	study	that	has	
simultaneously	evaluated	a	wide	range	of	addictive	risk	behaviors	associated	with	HCV	has	not	
been	conducted	to	date.	This	type	of	investigation	will	help	to	identify	at-risk	populations	for	
HCV	and	provide	valuable	information	regarding	how	one	might	efficiently	link	them	to	
appropriate	treatment	and	care.		
Aim:	
The	primary	aims	of	this	study	were	1).	To	estimate	chronic	HCV	infection	(CHI)	prevalence	in	
non-institutionalized	U.S.	adult	population	from	2003-2014	2).	To	perform	a	multivariate	
examination	of	all	known	behavioral	risk	factors	significantly	associated	with	CHI	and	3).	To	
identify	less	invasive	questions	regarding	risk	behaviors	associated	with	CHI	that	could	be	used	
to	predict	state-level	CHI	prevalence	using	other	state-specific	data	sources	such	as	The	
Behavioral	Risk	Factor	Surveillance	System	(BRFSS).		
Methods:	
The	study	utilized	nationally	representative	data	from	National	Health	and	Nutrition	
Examination	Survey	(NHANES)	for	the	years	2003-2014.	HCV	RNA	positive	persons	were	CHI	
positive	population.	Bivariate	analyses	were	performed	to	examine	the	frequency	distributions	
of	the	study’s	primary	dependent	variable	(CHI)	and	all	independent	variables	(demographical	+	
behavioral	risk	factor	variables).	The	analysis	sample	included	11,596	adults	aged	20-59	years.	
Risk	factors	for	CHI	were	examined	using	both	bivariate	and	multivariate	logistic	regression	
analyses.	We	first	conducted	weighted	bivariate	logistic	regression	analyses	to	examine	the	
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relationships	of	dependent	and	independent	variables	without	controlling	for	potential	
confounders.	We	then	conducted	weighted	multivariate	adjusted	logistic	regression	analyses	to	
examine	the	relationships	between	the	dependent	and	independent	variables	while	controlling	
for	potential	confounders.	Odds	ratios	(OR),	95%	confidence	limits	(CL)	and	p-values	were	
calculated.	A	p-value	<	0.05	was	considered	statistically	significant.	SAS	9.4	was	used	for	all	
statistical	analyses.		
Results:	
The	estimated	number	of	CHI	adults	aged	>/=	20	years	in	2014	was	1.93	million	leading	to	an	
estimated	CHI	prevalence	of	0.7%.	Injection	drug	users	(IDU)	had	the	highest	CHI	prevalence	of	
30.24%	by	bivariate	analyses.	Multivariate	logistic	regression	analysis	in	the	chronic	HCV	full	
model	indicated	that	age	categories	40-49	y	(OR:	7.9,	95%	CL:	3.8-16.2)	and	50-59	y	(OR:	8.0,	
95%	CL:	3.5-18.2);	non-Hispanic	blacks	(OR:	2.4,	95%	CL:	1.3-4.1);	less	than	high	school	
education	(OR:	2.6,	95%	CL:	1.5-4.8);	<	2.0	times	the	poverty	level	(OR:	3.5,	95%	CL:	1.9-	6.6);	
heroin	consumers	(OR:	2.3,	95%	CL:	1.1-4.6);	IDU	(OR:	8.1,	95%	CL:	3.1-21);	blood	transfusion	
recipients	(OR:	2.9,	95%	CL:	1.4-5.7)	and	>/=	10	lifetime	sex-partners	(OR:	5.5,	95%	CL:	1.5-19.7)	
were	significantly	associated	with	CHI.		
Multivariate	logistic	regression	analysis	in	the	chronic	HCV	risk	factor	model	indicated	that	
persons	in	moderate	(OR:	2.5,	95%	CL:	1.1-5.5)	and	high	(OR:	30.3,	95%	CL:	12.1-76)	substance	
abuse	risk	factor	categories	were	significantly	associated	with	CHI.	Multivariate	logistic	
regression	analysis	in	chronic	HCV	BRFSS	model	indicated	that	age	categories	40-49	y	(OR:	7.5,	
95%	CL:	3.5-15.9)	50-59	y	(OR:	8.7,	95%	CL:	4.2-18);	males	(OR:	3.1,	95%	CL:	1.5-6.4);	non-
Hispanic	black	(OR:	1.8,	95%	CL:	1.1-2.9);	less	than	high	school	education	(OR:	2.2,	95%CL:	1.3-
3.8);	<	2.0	times	the	poverty	level	(OR:	3.7,	95%	CL:	2.0-6.8);	alcohol	consumers	(OR:	1.7;	95%	
CL:	1.0-2.9)	and	smokers	(OR:	3.7,	95%	CL:	1.8-7.6)	were	significantly	associated	with	CHI.	c-
statistic	of	the	three	models	were	0.94,	0.92	and	0.88	respectively	thereby	implying	that	all	
three	models	were	strong	models	with	a	higher	predictive	accuracy	of	CHI.		
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Conclusions:	
We	conclude	that	the	estimated	prevalence	of	CHI	in	this	analysis	sample	is	0.7%,	however	the	
true	prevalence	estimates	of	CHI	are	likely	to	be	significantly	higher	if	incarcerated,	homeless	
and	other	population	not	presented	in	NHANES	are	included.	IDU	continues	to	be	the	strongest	
risk	factor	for	CHI.	Persons	with	two	or	more	addictive	behavioral	risk	factors	have	significant	
associations	with	CHI.	Results	from	this	study	will	enable	identification	of	at-risk	population	for	
CHI	and	provide	valuable	information	for	linking	them	to	appropriate	treatment	and	care.			
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CHAPTER	ONE	
INTRODUCTION	
1.1	Background	
						Hepatitis	C	virus	(HCV)	infection	is	the	most	common	blood-borne	infection	worldwide.	In	
1989,	Choo	et	al	(1)	successfully	cloned	a	single	cDNA	clone	derived	from	a	new	flavi-like	virus	
by	various	molecular	biological	methods.	This	virus	was	responsible	for	most	post-transfusion	
hepatitis,	also	called	type	C	hepatitis,	parenterally	transmitted	non-A	non-B	hepatitis	(PT-
NANB),	non-B	transfusion-associated	hepatitis,	post-transfusion	non-A	non-B	hepatitis,	and	this	
virus	was	identified	as	HCV	(2).	Globally,	up	to	3%	of	the	world’s	population,	which	is	about	200	
million	individuals,	are	estimated	to	have	HCV	infection	(3);	~71	million	are	estimated	to	have	
CHI	out	of	which	400,000	deaths	occur	due	to	cirrhosis	and	hepatocellular	carcinoma	because	
of	CHI	(World	Health	Organization	Fact	Sheet,	October	2017).	In	the	civilian	non-
institutionalized	U.S.	population,	approximately	2.7	million	persons	have	CHI	(4).		
				HCV	infection	remains	asymptomatic	in	many	persons	and	approximately	half	the	infected	
are	unaware	of	their	infection.	Within	30	years,	41%	of	infected	persons’	progress	to	cirrhosis,	
hepatocarcinoma	and	mortality	from	liver-related	causes	(5).	A	majority	of	the	infected	do	not	
receive	antiviral	treatment	because	they	are	unaware	of	their	infection	(6).	Due	to	these	
reasons,	the	quality	of	life	(QOL)	is	negatively	affected	in	the	infected	population	along	with	
exorbitant	health	care	costs	associated	with	treatment	and	care	of	the	infected.	Therefore,	it	is	
important	to	identify	the	at-risk	population	for	HCV	infection	and	direct	them	to	appropriate	
treatment	and	care	to	positively	impact	the	QOL	and	decrease	the	healthcare	associated	costs.		
Anti-HCV	positive	persons	are	positive	to	HCV	antibody	which	indicate	prior	or	current	Hepatitis	
C	virus	infection	termed	as	acutely	infected	population	and	HCV	RNA	positive	persons	indicate	
current	infection	termed	as	chronically	infected	population.	Chronic	HCV	infection	(CHI)	is	
developed	from	acute	HCV	infection	in	the	affected	population.		
1.2	Purpose	of	this	study	
							Denniston	et	al	(4)	have	conducted	a	comprehensive	study	for	determination	of	risk	factors	
associated	with	CHI	in	the	US	non-institutionalized	population	between	2003-2010.	This	is	the	
most	comprehensive	study	conducted	to	date	where	associations	between	behavioral	risk	
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factors	and	CHI	were	determined.	It	would	be	useful	to	examine	all	possible	risk	factors	
associated	with	CHI	to	better	identify	the	at-risk	populations.	It	would	also	be	useful	to	better	
characterize	the	risk	associated	with	CHI	by	developing	summary	measures	of	risk	which	could	
be	used	in	clinic	settings	and/or	in	future	studies	for	identification	of	at-risk	individuals	for	CHI	
who	should	be	tested	and	treated.	In	addition,	it	will	be	helpful	to	estimate	CHI	prevalence	at	
the	state	or	county	levels	by	using	predictive	models.	In	this	study,	we	propose	to	fill	these	gaps	
by	conducting	a	multivariate	examination	of	all	possible	risk	factors	of	CHI	in	the	non-
institutionalized	U.S.	adult	population	using	National	Health	and	Nutrition	Examination	Survey	
(NHANES)	datasets	from	2003-2014.		
1.3	Research	Questions		
						Research	questions	asked	in	this	study	are	below,	
1. Is	there	an	association	between	age,	sex,	race/ethnicity,	marital	status,	education	and	
family	income	with	CHI	after	adjusting	for	confounders	in	the	US	adult	population	20	–	
59	years	of	age?	
2. Is	there	an	association	between	smoking,	alcohol	consumption,	illegal	drug	use,	
injection	drug	use,	blood	transfusion	and	lifetime	sex-partners	with	CHI	after	adjusting	
for	confounders	in	the	US	adult	population	20	–	59	years	of	age?	
3. Does	the	odds	of	CHI	increase	with	increasing	number	of	substance	abuse	risk	factors	in	
the	US	adult	population	20	–	59	years	of	age?	
4. Can	the	risk	for	CHI	in	the	US	adult	population	20	–	59	years	of	age	be	modeled	without	
sensitive	behavioral	information	regarding	risk	factors	such	as	illegal	drug	use	or	number	
of	sexual	partners	so	that	predictive	models	of	CHI	prevalence	could	be	developed	from	
other	data	sources	that	do	not	include	such	sensitive	behavioral	information?	
1.4	Hypotheses	
						Our	hypotheses	are,		
1. One	or	more	of	the	demographical	variables	in	1.3.1	is	significantly	associated	with	CHI	
by	adjusted	multivariate	analysis.		
2. One	or	more	of	the	behavioral	risk	factors	and/or	blood	transfusion	in	1.3.2	is	
significantly	associated	with	CHI	by	adjusted	multivariate	analysis.		
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3. Prevalence	and	odds	of	CHI	significantly	increases	with	associations	with	increasing	
number	of	substance	abuse	risk	factors.		
1.5	Organization	of	the	thesis	
							This	thesis	is	organized	into	five	chapters.	Chapter	one	is	the	Introduction	which	describes	
the	background	of	the	study,	purpose	of	this	study,	research	questions	and	hypotheses.	
Chapter	two	is	the	Literature	Review	followed	by	detailed	description	of	the	Methodology	in	
Chapter	three.	Chapter	four	details	the	Results	and	Chapter	Five	is	composed	of	Discussion,	
Study	Limitations	and	Conclusions.		
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CHAPTER	TWO	
LITERATURE	REVIEW	
2.1	Hepatitis	C	is	a	liver	disease	caused	by	the	Hepatitis	C	virus:	biology	and	pathology	
						HCV	first	characterized	in	1989	by	Choo	et	al	(1)	and	Kuo	et	al	(7)	is	an	enveloped	RNA	virus	
of	the	genus	Hepacivirus	of	the	family	Flaviviridae.	Its	genome	consists	of	9.6-kb	single-stranded	
RNA	which	codes	for	a	long	polyprotein	of	approximately	3000	amino	acids	which	is	processed	
post-translationally	to	yield	structural	proteins	(core	and	envelope	proteins	E1,	E2)	and	non-
structural	(NS)	proteins.	The	envelope	proteins	are	the	outer	surface	proteins	of	the	viral	
particles	which	play	a	key	role	in	virus	entry	into	the	host	cell	(8).	HCV	RNA	virus	has	a	high	
degree	of	heterogeneity	resulting	in	six	major	genotypes	and	more	than	120	subtypes	of	HCV	
(9).	
						There	are	three	major	types	of	HCV	genotypes-	genotype	1	(GT1),	genotypes	2	and	3	(GT2	
and	GT3)	that	influence	disease	progression	and	responses	to	therapy.	In	the	US,	GT1	is	the	
most	prevalent	as	it	is	affects	~70%	of	patients	while	GT2	and	GT3	affect	~13%	of	patients	with	
HCV.	
2.2	Acute	and	Chronic	HCV	infection,	its	comorbidities	
					Hepatitis	C	is	a	contagious	liver	disease	that	ranges	in	severity	from	a	mild	illness	lasting	a	
few	weeks	to	a	serious,	lifelong	illness	that	attacks	the	liver.	Acute	Hepatitis	C	virus	infection	is	
a	short-term	illness	that	occurs	within	the	first	6	months	after	infection	with	HCV.	Acute	HCV	is	
usually	asymptomatic	and	about	15-45%	of	the	infected	spontaneously	clear	the	virus	by	a	
strong	immune	response	without	any	treatment	within	6	months	of	infection.	Acute	HCV	is	a	
contagious	viral	infection	spread	through	contact	with	infected	blood	and	bodily	fluids.	Chronic	
Hepatitis	C	virus	infection	is	a	long-term	illness	that	occurs	when	the	HCV	RNA	remains	in	a	
person’s	body	for	at	least	6	months	after	viral	transmission	(10).	In	55-85%	of	the	population	
that	don’t	clear	the	virus	after	an	acute	HCV	infection,	it	will	develop	into	a	chronic	HCV	
infection	(CHI).	The	presence	of	hypervariable	regions	in	the	E2	envelope	glycoprotein,	lack	of	
proof	reading	ability,	high	rate	of	generating	new	viral	variants	during	infection,	ability	to	evade	
the	host	immune	responses	together	allow	HCV	to	persist	in	the	infected	persons	and	establish	
	 17	
into	a	CHI	(11).	In	those	people	who	develop	CHI,	the	infection	is	often	undiagnosed	because	it	
remains	asymptomatic	until	decades	after	infection	when	symptoms	develop	and	lead	to	
serious	liver	problems,	including	hepatitis,	cirrhosis	(scarring	of	the	liver)	or	liver	cancer	(Figure	
1).	Persistent	HCV	infection	is	accompanied	by	liver	cirrhosis,	hepatocellular	carcinoma	(HCC),	
end	stage	liver	disease	and	finally	death	(12).	
						Lu	etal	(13)	carried	out	The	Chronic	Hepatitis	Cohort	Study	(CHeCS)	that	comprised	of	
11,167	adults	with	CHI	receiving	care	at	one	of	four	large	health	systems	and	studied	changing	
trends	in	rates	of	cirrhosis,	decompensated	cirrhosis	and	all-cause	mortality.	Results	from	this	
study	showed	that	prevalence	of	cirrhosis	increased	from	20.8%	to	27.6%	from	2006	to	2015	in	
chronic	HCV	patients.	Their	study	showed	that	HCV	patients	>/60	years	of	age	had	the	highest	
prevalence	of	liver-related	complications	when	compared	to	younger	patients	<60	years	of	age.	
Similar	findings	were	published		by	El-	Serag	et	al	(14)	from	their	retrospective	cohort	study	of	
161,744	chronic	HCV	patients	in	the	Veterans	Health	Administration	Hepatitis	C	Clinical	Case	
Registry.	Persistent	HCV	infection	is	accompanied	by	liver	cirrhosis,	hepatocellular	carcinoma	
(HCC),	end	stage	liver	disease	and	finally	death	(12).	Kanwal	etal	(15)	conducted	a	retrospective	
cohort	study	of	approximately	110,000	US	veterans	with	CHI	of	known	HCV	genotypes	1,	2,	3,	
and	4	from	the	VA	HCV	Clinical	Case	Registry	between	2000	and	2009.	Results	from	this	study	
showed	that	HCV	GT3	was	associated	with	a	significantly	increased	risk	of	developing	cirrhosis	
and	hepatocarcinoma	when	compared	to	genotype	1.		
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Figure	1:	Natural	history	of	hepatitis	C	virus	infection	(16)	
2.3	HCV	related	healthcare	costs	
						The	quality-adjusted	life	year	(QALY)	is	a	generic	measure	of	disease	burden,	which	includes	
both	measures	of	morbidity	(self-reported	health)	and	mortality	to	assess	the	quality	and	
quantity	of	life,	lived.	It	is	used	in	economic	evaluation	to	assess	the	value	for	money	of	medical	
interventions.	One	QALY	is	equal	to	one	year	in	perfect	health.	In	their	study,	Younossi	et	al	
compared	the	cost-effectiveness	(CE)	of	three	HCV	screening	strategies	for	treatment	with	oral	
direct	acting	antiviral	drugs	(DAA).	The	three	strategies	were	screen	all	(SA),	screen	Birth	Cohort	
(BCS),	and	screen	high	risks	(HRS).	SA	cost	$272.0	billion	with	12.19	QALYs	per	patient,	BCS	cost	
$274.5	billion	and	led	to	11.65	QALYs	per	patient	and	HRS	cost	$284.5	billion	with	11.25	QALYs	
per	patient.	This	study	concluded	that	screening	the	entire	US	population	and	treating	active	
viraemia	as	cost-saving	(17).	
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							Davis	et	al	(18)	conducted	a	case-control	study	where	they	analyzed	a	large	United	States	
claims	database	(from	1/1/2002	to	12/31/2006)	to	estimate	all-cause	and	disease-related	
resource	utilization	and	costs	among	managed	care	enrollees	with	chronic	HCV.	Use	and	costs	
of	medical	services	and	prescription	drugs	over	a	12-month	post-diagnosis	period	were	
determined.	Results	from	this	study	showed	that	adjusted	all-cause	costs	were	$20,961	per	
HCV	patient	when	compared	with	$5451	per	control	(p<0.0001).	Hospitalization	occurred	in	
24%	of	HCV	patients	when	compared	with	7%	of	controls	(p<0.0001).	This	study	concluded	that	
disease-related	costs	in	HCV	exceeded	all-cause	costs	in	demographically	matched	controls.		
Total	healthcare	cost	associated	with	HCV	infection	in	2011	was	$6.5	($4.3-$8.2)	billion	which	is	
expected	to	peak	in	2024	at	$9.1	($6.4-$13.3)	billion	(19).	Majority	of	this	peak	cost	will	be	
attributable	to	advanced	liver	diseases	such	as	decompensated	cirrhosis	(46%),	compensated	
cirrhosis	(20%)	and	HCC.	Hunter	et	al	(20)	performed	a	retrospective	study	of	chronic	HCV	
patients	to	determine	the	relationships	between	HCV	genotypes	and	liver	disease	progression,	
healthcare	resource	utilization	(HCRU)	and	healthcare	costs.	This	study	showed	that	patients	
with	GT1	had	the	highest	total	all-cause	costs,	patients	with	GT3	had	the	highest	liver-related	
comorbidities	and	patients	with	GT2	had	lower	HCRU	and	the	lowest	costs.	GT3	is	associated	
with	higher	risk	of	liver	complications	that	leads	to	increased	health	care	cost	(21,	22).		
						In	a	recent	study	El	Khoury	et	al	(23),	estimated	the	burden	of	untreated	HCV	infection	in	
patients	associated	with	high	economic	costs	and	reduced	quality	of	life	in	comparison	with	
matched	controls.	Annual	productivity	losses	of	untreated	HCV	infection	patients	were	
significantly	higher	when	compared	with	matched	controls	($8,209	vs.	$4,424,	p	<	0.001)	and	
the	average	total	costs	were	approximately	$27,000	per	untreated	HCV	infected	patient	per	
year	which	was	about	150%	of	the	total	costs	of	the	matched	controls.	This	study	also	showed	
that	untreated	HCV	infected	patients	had	significantly	lower	health	related	quality	of	life	
(HRQoL)	than	matched	controls.			
						The	advent	of	DAAs	has	been	revolutionary	in	the	advancement	of	HCV	treatment.	DAAs	
have	fewer	side	effects,	shorter	duration	times	(~12	weeks)	for	treatment,	high	sustained	
virologic	response	(SVR)	and	are	effective	regardless	of	race	and	gender.	Exorbitant	prices	of	
DAAs	serve	as	a	major	obstacle	to	the	wide	use	of	these	drugs	for	HCV	treatment.	Average	cost	
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per	pill	is	~$1000	and	approximate	cost	of	treatment	for	12	weeks	is	$84,000	(24).	However,	in	
August	2017	Food	and	Drug	Administration	(FDA)	has	approved	two	new	DAAs	to	treat	all	
genotypes	of	HCV.	AbbVie’s	Mavyret	(glecaprevir/pibrentasvir)	was	approved	and	launched	for	
a	reduced	price	of	$26,400	for	8	weeks	(www.mavyret.com).	This	lower	cost	is	partly	due	to	its	
shorter	treatment	duration,	but	even	people	who	need	12	or	16	weeks	would	still	pay	less	than	
they	would	for	existing	therapies.		
2.4	Estimation	of	prevalence	gives	us	key	information	about	the	scope	of	the	problem	
						HCV	prevalence	is	highest	in	Africa	and	the	Middle	East	ranging	from	2	–	15%,	whereas	
prevalence	in	North	America,	Japan,	Australia,	Northern	and	Western	Europe	is	the	lowest	not	
>2%.	Egypt	has	the	highest	HCV	prevalence	(25,	26).	In	the	United	States	non-institutionalized	
civilian	population,	NHANES	estimated	that	approximately	2.7	million	persons	are	chronically	
infected	with	HCV	and	about	3.6	million	people	are	acutely	infected	with	HCV	between	2003	
and	2010	(4).	Studies	conducted	earlier	between	1988	and	1994	yielded	a	similar	estimate	of	
the	US	population	with	CHI	of	2.7	million	persons	(27)	and	3.2	million	persons	had	CHI	between	
1999	and	2002	(28).	However,	these	numbers	underestimate	the	true	prevalence	because	
NHANES	does	not	include	institutionalized	population,	which	is	at	a	high-risk	of	HCV	infection.	
Edlin	et	al	(29)	conducted	a	systematic	review	of	peer-reviewed	literature	and	unpublished	
presentations	to	estimate	the	prevalence	of	hepatitis	C	in	the	excluded	populations	in	the	US.	
An	estimated	1.0	million	HCV	antibody	positive	persons	are	excluded	from	the	NHANES	
sampling	frame	and	0.8	million	are	currently	infected	leading	to	a	total	of	at	least	4.6	million	
with	HCV	antibody	and	3.5	million	currently	infected.		
						Overall	prevalence	of	cirrhosis	in	HCV-infected	patients	increased	from	20.8%	in	2006	to	
27.6%	in	2015	and	overall	prevalence	of	decompensated	cirrhosis	increased	from	9.3%	in	2006	
to	10.4%	in	2015	in	HCV	infected	patients	aged	60	or	older	(13).	The	high	prevalence	of	HCV	
and	HCV	mediated	comorbidities	in	the	US	indicate	the	persistence	of	HCV	infection	since	its	
discovery	in	1989	due	to	numerous	reasons	inclusive	but	not	limited	to	higher	rates	of	
treatment	costs,	undiagnosed	and/or	untreated	infections	and	behavioral	risk	factors	among	
others.		
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2.5	Risk	Factors	for	HCV	infection	–	Demographic	and	Behavioral	risk	factors	
						HCV	infection	in	patients	is	primarily	spread	by	blood	contact.	Intravenous	drug	injection	is	
the	primary	risk	factor	associated	with	new	HCV	infections.	Therefore	the	three	primary	risk	
groups	are	intravenous	drug	users,	recipients	of	blood	transfusion	before	1992	and	health	care	
workers	(30).	Since	1992,	blood	donors	are	routinely	screened	for	HCV	to	eliminate	HCV	
infected	blood	in	the	process	of	blood	transfusion.	Alter	et	al	(27)	were	the	first	to	study	
prevalence	of	HCV	in	the	US	using	NHANES	datasets	by	behavioral	risk	factors.	In	this	study	
conducted	to	estimate	prevalence	of	HCV	from	1988	–	1994,	the	authors	determined	that	
illegal	drug	use	and	high-risk	sexual	behavior	were	the	strongest	risk	factors	independently	
associated	with	HCV	infection	among	participants	17	to	59	years	of	age.	Increased	prevalence	
of	HCV	infection	was	associated	with	increasing	number	of	times	cocaine	or	marijuana	was	
used	and	highest	prevalence	of	HCV	infection	was	seen	among	persons	who	had	10	or	more	
sexual	partners.		
						HCV	seroprevalence	has	been	reported	in	75-90%	of	long-term	(>3	years)	injection	drug	
users	(IDU)	and	in	18%-38%	of	short-term	(<3	years)	IDUs	(31-33).	It	is	also	a	known	fact	that	
injection	drug	use	is	the	strongest	risk	factor	independently	associated	with	HCV	infection.	For	
example,	the	1945-1965	birth	cohort	is	an	important	predictor	for	anti-HCV	positivity	because	
of	high	rates	of	injection	drug	use	in	this	cohort	termed	the	baby	boomers’	cohort.	In	2012,	CDC	
issued	a	recommendation	to	test	all	persons	born	in	this	cohort	for	HCV	infection	without	prior	
risk	ascertainment	(34).	This	was	further	supported	by	the	findings	from	Smith	et	al	(35)	who	
determined	the	prevalence	and	predictors	of	anti-HCV	positivity	among	primary	care	
outpatients	using	risk-based	testing	that	74%	of	the	identified	anti-HCV	positive	patients	were	
born	between	1945-1965.	Anti-HCV	positivity	was	significantly	higher	in	these	patients	when	
compared	with	the	referent	group	of	those	born	before	1945	or	after	1965.		
						Patients	undergoing	hemodialysis	are	at	a	higher	risk	for	HCV	infection	with	a	prevalence	
estimate	of	0.8%	of	HCV	antibodies	in	the	US	(36).	Prevalence	in	hemodialysis	patients	has	been	
found	to	increase	with	longer	hemodialysis	duration,	male	sex,	black	ethnicity,	comorbidities	
(example:	diabetes,	hepatitis	B),	prior	kidney	transplant,	alcohol	or	drug	abuse	(37).	
Demographic	risk	factors	such	as	male	sex,	older	age	of	40-59	years,	non-hispanic	black,	lesser	
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than	high	school	education	and	lower	family	income	were	determined	to	be	significantly	and	
independently	associated	with	HCV	infection	by	Denniston	et	al	(4).		
2.6	Public	health	impact	of	examination	of	comprehensive	behavioral	risk	factors	for	CHI		
						Various	studies	listed	in	this	review	have	examined	one	or	more	of	the	risk	factors	
associated	with	HCV	infection	inclusive	of	demographic	factors	such	as	age	40-59	years,	male	
sex,	lower	family	income,	non-Hispanic	black	ethnicity,	1945-1965	birth	cohort	and	behavioral	
factors	such	as	illegal	drug	use,	alcohol	use	and	>/=	10	life	time	sex-partners.	Denniston	et	al	(4)	
conducted	a	comprehensive	study	by	examination	of	the	aforementioned	demographic	risk	
factors,	illicit	drug	use	and	receipt	of	blood	transfusion	before	1992	and	determined	that	
persons	aged	40-59	years,	non-Hispanic	black,	less	than	high	school	education,	illicit	drug	use	
and	receipt	of	blood	transfusion	before	1992	were	significantly	associated	with	CHI.		
						Comprehensive	risk	factor	profile	may	include	a	combination	of	different	types	of	illicit	
drugs,	injection	drugs,	alcohol	use,	smoking,	and	>10	lifetime	sex-partners.	Examination	of	
comprehensive	profile	of	behavioral	risk	factors	for	CHI	will	help	to	refine	identification	of	the	
populations	at	risk	for	CHI,	enabling	screening,	behavioral	interventions,	and	linking	them	to	
care	and	treatment.	Up-to-date,	an	estimation	of	CHI	prevalence	using	comprehensive	
behavioral	risk	factor	profile	has	not	been	published.	In	our	study,	we	propose	to	estimate	the	
prevalence	of	CHI	in	the	US	non-institutionalized,	civilian	population	using	NHANES	datasets	
from	2003-2014.	We	will	determine	comprehensive	behavioral	risk	factors	associated	with	CHI,	
which	will	improve	identification	of	at	risk	populations	to	link	them	to	optimal	treatment,	care,	
prevention	of	comorbidities	and	reduce	the	associated	health	care	costs.	Estimates	of	CHI	
burden	are	essential	to	guide	policy	and	programs	to	optimally	prevent,	detect	and	treat	the	
infection.	State-level	estimates	of	the	CHI	prevalence	are	essential	for	developing	intervention	
programs,	research,	and	federal	assistance	funding	priorities	among	US	states.	Results	from	this	
thesis	will	be	critical	to	develop	a	prediction	model	for	estimation	of	state-level	prevalence	of	
CHI	where	less	information	on	behavioral	risk	factors	are	available.		
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CHAPTER	THREE	
METHODOLOGY	
3.1	Data	Source	
						We	performed	secondary	data	analyses	using	the	Centers	for	Disease	Control	and	
Prevention’s	National	Center	for	Health	Statistics	survey	called	NHANES.	This	survey	collects	
nationally	representative	data	on	the	health	and	nutritional	status	of	the	U.S.	
noninstitutionalized	civilian	population	and	is	a	public	use	dataset.	In	this	study,	we	combined	
data	from	several	NHANES	data	sources	including	demographic	information,	laboratory	testing	
and	questionnaire	datasets	from	subjects	interviewed	between	2003-2014.	NHANES	provides	
information	on	the	non-institutionalized	civilian	resident	population.	It	excludes	persons	in	care	
or	custody	of	institutionalized	settings,	all	active-duty	military,	all	active-	duty	family	members	
living	overseas,	and	US	citizens	living	outside	of	the	50	states	and	District	of	Columbia	(38).		
3.2	Survey	and	Sample	design	
						NHANES	examines	a	nationally	representative	sample	of	about	5,000	persons	each	year	
located	in	counties	across	the	US.	The	NHANES	interview	includes	demographic,	
socioeconomic,	dietary,	and	health-related	questions.	The	examination	component	consists	of	
medical,	dental,	and	physiological	measurements,	as	well	as	laboratory	tests	administered	by	
highly	trained	medical	personnel.	Findings	from	the	survey	was	used	to	determine	the	
prevalence	of	major	diseases	and	risk	factors	for	diseases.		
						A	four-stage	sample	design	was	implemented	in	the	datasets	used	in	this	study.	The	first	
stage	primary	sampling	units	(PSUs)	were	selected	from	a	frame	of	all	U.S.	counties;	the	
second-stage	included	a	sample	of	area	segments	such	as	census	blocks;	the	third-stage	sample	
selection	consisted	of	dwelling	units	(DUs)	such	as	noninstitutionalized	group	quarters	and	the	
fourth	stage	consisted	of	persons	within	DUs	or	households	(38).		
3.3	Demographics	Variables	
						Sample	persons	demographics	data	files	for	2003-2004,	2005-2006,	2007-2008,	2009-2010,	
2011-2012	and	2013-2014	were	downloaded	from	the	NHANES	website	for	each	cohort	
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(https://wwwn.cdc.gov/Nchs/Nhanes/2003-2004/DEMO_C.htm).	Following	is	the	list	of	
demographic	variables	used	in	this	study,		
1. RIDAGEYR-	Age	and	screening	Adjudicated,	categorical	variable.	This	is	the	age	of	the	
sample	person	at	the	time	of	the	screening	interview.	From	1	through	84	years	of	age,	
age	of	the	sample	person	is	reported	by	single	year	of	age.	Adults	85	years	and	older	
have	a	value	of	85.	In	this	study,	age	categories	were	0-19,	20-39,	40-59,	60	plus.		
2. RIDRETH1-	Race/Ethnicity.	This	categorical	variable	was	derived	from	responses	to	the	
survey	questions	on	race	and	Hispanic	origin.		In	this	study,	all	other	races	except	non-
Hispanic	black	were	recoded	into	a	‘Other	Races’	category.		
3. RIAGENDR-	Gender,	categorical	variable.	Females	were	the	referent	group	in	adjusted	
and	unadjusted	logistic	regression	models	in	this	study.		
4. DMDEDUC2-	Education	level,	adults	20+,	continuous	variable.	This	variable	is	the	highest	
grade	or	level	of	education	completed	by	adults	20	years	and	older.	Range	of	value	
descriptions	are	less	than	9th	grade,	9-11th	grade,	high	school/	General	Equivalency	
Diploma	(GED),	some	college	or	associate	degree,	college	graduate	or	above.	Response	
categories	were	recoded	into	less	than	high	school	graduate/GED	education	and	greater	
than	high	school	graduate/GED	education.		
5. DMDMARTL-	Marital	Status,	categorical	variable.	Response	categories	in	this	variable	
were	recoded	into	i).	Never	married,	ii).	Widowed/Separated/Divorced	and	iii).	
Married/Living	with	partner.	
6. INDFMPIR-	Family	Poverty	to	Income	Ratio,	categorical	variable.	This	variable	is	an	index	
for	the	ratio	of	family	income	to	poverty.	This	variable	was	calculated	by	dividing	family	
income	by	the	poverty	guidelines	specific	to	the	family	size,	state	and	year.	Response	
values	in	this	variable	were	recoded	into	i).	<	2.0	times	the	family	income	to	poverty	
ratio	and	ii).	>/=	2.0	times	the	family	income	to	poverty	ratio.		
3.4	Behavioral	Risk	Factor	Variables	
						Sample	persons	questionnaire	data	files	for	behavioral	risk	variables	were	downloaded	from	
respective	cohorts	from	NHANES	website	
(https://wwwn.cdc.gov/nchs/nhanes/search/datapage.aspx?Component=Questionnaire&Cycle
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BeginYear=2005).	Alcohol	use,	drug	use,	smoking	and	sexual	behavior	variables	were	the	
behavioral	risk	variables	while	blood	transfusion	was	the	medical	examination	variable	in	this	
study.		
Blood	Transfusion	variable	
I. MCQ092:	Ever	receive	blood	transfusion	
Alcohol	variables	
I. Alq101:	Had	at	least	12	alcohol	drinks/year	
II. Alq110:	Had	at	least	12	alcohol	drinks/lifetime	
III. Alq130:	Average	number	of	alcoholic	drinks/day	in	the	past	12	months	
Four	alcohol	categories	were	created	by	recoding	the	alcohol	variables	as	follows	(39),	
• Alcohol	category	1:	Lifetime	abstainers	<	12	drinks	ever	
• Alcohol	category	2:	Former	drinkers	>/=	12	drinks	in	their	lifetime	but	none	in	the	past	
year	
• Alcohol	category	3:	Non-excessive	current	drinkers	on	average	reported	
• Male	gender:	</=	14	drinks/week	
• Female	gender:	</=	7	drinks/week	
• Alcohol	category	4	=	Excessive	current	drinkers	reported	
• Male	gender:	>	14	drinks/week	
• Female	gender:	>	7	drinks/week	
						These	were	further	condensed	into	two	alcohol	risk	categories	where	alcohol	categories	1,	
2,	3	were	classified	as	sample	persons	with	no	alcohol	risk	and	alcohol	category	4	was	classified	
as	sample	persons	with	alcohol	risk.		
Drug	variables	
For	2003-2004	cohort	following	variables	were	recoded	into	ever-inject	variable	in	this	study,	
I. Duq120:	Ever	used	needle	to	take	drugs	
II. Duq100:	Ever	used	cocaine	or	other	street	drug	
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Variables	for	use	of	marijuana	or	hashish,	cocaine,	heroin	and	methamphetamine	were	not	
available	for	this	cohort.		
For	2005-2014	cohorts	following	variables	were	used	which	were	recoded	into	variables	as	
indicated	below,	
I. Duq200:	Ever	used	marijuana	or	hashish	which	was	recoded	as	evermarijuana	
II. Duq240:	Ever	used	cocaine/heroin/methamphetamine	
III. Duq250:	Ever	used	any	form	of	cocaine	along	with	duq240	were	recoded	as	evercocaine	
IV. Duq290:	Ever	used	heroin	along	with	duq240	were	recoded	as	heroin	
V. Duq330:	Ever	used	methamphetamine	along	with	duq240	were	recoded	as	
evermethamphetamine	
VI. Duq370:	Ever	used	needle	to	inject	illegal	drug	was	recoded	as	everinject       	
Smoking	variable	
I. Smq020:	Smoked	at	least	100	cigarettes	in	life	was	recoded	as	ever_smoked	
Sexual	behavior	
For	all	cohorts,	following	variables	were	recoded	into	lifetime	sex-partners	(Table	1).	
Table	1:	Lifetime	sex-partners	variable	and	recode	
Cohort	 Variable	name	for	
number	of	female	sex-
partners/lifetime	(A)	
Variable	name	for	
number	of	male	sex-
partners/lifetime	(B)	
Variable	recode	into	
lifetime	sex-
partners	
2003-2004	 Sxq170	 Sxq200	 A+B	
2005-2014	 Sxq171	 Sxq101	 A+B	
	
3.5	Laboratory	Testing	
						Laboratory	testing	was	carried	out	to	detect	anti-HCV	in	blood	or	serum	using	direct	solid-
phase	enzyme	immunoassay	(VITROS	Anti-HCV	Immunodiagnostic	System,	Ortho	Clinical	
Diagnostics,	Rochester,	New	York).	A	confirmatory	recombinant	immunoblot	assay	(RIBA)	(RIBA	
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HCV	3.0	Strip	Immunoblot	Assay,	Emeryville,	California)	an	in	vitro	qualitative	immunoassay	
was	performed	for	the	detection	of	anti-HCV	in	human	blood	or	serum.	Samples	with	positive	
results	on	RIBA	testing	were	confirmed	as	positive	for	anti-HCV,	with	negative	results	were	
reported	as	confirmed	negative	for	anti-HCV	and	those	with	indeterminate	results	were	
reported	as	indeterminate.		
						Chronically	infected	persons	are	currently	infected	and	it	is	important	in	clinical	practice	to	
identify	these	persons.	Serum	samples	that	were	confirmed	positive	or	indeterminate	for	anti-
HCV	were	further	tested	for	HCV	RNA	using	COBAS	AMPLICOR	HCV	Test,	version	2.0	(Roche	
Diagnostics,	Indiana,	US)	an	in-vitro	nucleic	acid	amplification	for	HCV	RNA	on	the	COBAS	
AMPLICOR	Analyzer	(Roche	Diagnostics)	for	samples	from	2003	to	2010,	2012-2014	and	the	
AMPLIPREP	COBAS	TaqMan	HCV	Test	performed	on	the	COBAS	AMPLIPREP	and	COBAS	
TaqMAN	48	Analyzer	for	samples	from	2011-2012	(4).		
						Sample	persons	laboratory	data	files	for	HCV	RNA	were	downloaded	from	respective	
cohorts	from	the	NHANES	website	
(https://wwwn.cdc.gov/nchs/nhanes/search/datapage.aspx?Component=Laboratory&CycleBeg
inYear=2003).	For	2003-2004,	SSHCVRNA	was	the	HCV	RNA	variable.	Exam	sample	weights	were	
used	for	the	analysis	of	this	cohort.	For	rest	of	the	cohorts	LBXHCR	was	the	HCV	RNA	variable	
used	without	the	exam	sample	weights	since	it	was	not	required.		
I. SSHCVRNA:	Hepatitis	C	RNA	
II. LBXHCR:	Hepatitis	C	RNA	
3.6	Statistical	Analyses:	
						SAS	version	9.4	developed	by	the	SAS	Institute	(NC,	USA)	a	statistical	package	designed	to	
analyze	complex	survey	data	was	used	for	all	analyses	in	this	study.	Estimates	were	weighted	to	
represent	the	total	U.S.	noninstitutionalized	civilian	population,	to	account	for	oversampling	
and	nonresponse	to	the	household	interview	and	medical	examination.	Two-year	sample	
weights	(WTMEC2R)	were	used	for	the	weighted	analyses.	A	p	value	less	than	0.05	was	
considered	statistically	significant.		
	 28	
						For	descriptive	statistics,	to	estimate	the	prevalence	of	CHI	persons	with	demographic	
characteristics	such	as	age	such	as	smoking,	alcohol	use,	illegal	drugs	use	(marijuana,	cocaine,	
methamphetamine,	heroin	and	injection	drugs),	blood	transfusion	and	number	of	lifetime	sex-
partners	we	have	implemented	bivariate	analyses.	We	created	an	ordinal	variable	with	the	
number	of	risk	factors	-	0,	1,	2,	3,	4,	5,	6,	7	for	calculation	of	risk	factor	scores	for	CHI.		
						We	have	conducted	unadjusted	and	adjusted	weighted	multivariate	logistic	regression	
analyses	for	determination	of	risk	factors	significantly	associated	with	CHI	in	persons	of	age	20	
to	59	years	because	data	on	drug	use	and	sexual	behaviors	in	persons	<	20	years	and	>/=	60	
years	of	age	are	not	available	from	NHANES.		
						We	have	included	and	analyzed	missing	data	cases	as	a	separate	domain	rather	than	
excluding	the	data	from	the	analyses	because	missing	data	is	not	always	completely	at	random	
and	its	inclusion	accounts	for	the	accurate	analyses	of	the	entire	data	sets.	We	have	used	the	
Not	Missing	Completely	at	Random	(NOMCAR)	option	in	weighted	logistic	regression	models	to	
include	the	missing	data.	The	following	groups	were	used	as	referent	groups	for	the	analysis	
variables	used	in	logistic	regression	models:	
1. Age	=	20-39	y	
2. Sex	=	Female	
3. Race/Ethnicity	=	All	others	except	non-Hispanic	black	
4. Marital	=	Married,	living	with	partner	
5. Education=	High	school	or	more	
6. Family	income	=	>=	2.0	times	poverty	level	
7. Smoking	=	Never	smoked	
8. Alcohol	consumption	=	combined	3	groups	(i.e.,	never	drinkers,	former	drinkers,	and	
non-excessive	current	drinkers)	
9. Marijuana	=	Never		
10. Cocaine	=	Never	
11. Heroin	=	Never	
12. Methamphetamine	=	Never	
13. Injection	drug	use	(IDU)	=	Never	
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14. Blood	Transfusion	=	No	
15. Lifetime	Sex-partners	=	0-1	lifetime	sex-partners	
						For	unadjusted	and	adjusted	multivariate	logistic	regression	analyses,	we	have	pursued	
three	models	to	determine	the	association	between	risk	factors	and	CHI.	They	are		
1).	Chronic	HCV	full	model	(Model	1)	-	In	this	model,	we	have	included	all	the	demographic	and	
behavioral	risk	factors	mentioned	in	this	study	to	assess	the	associations	with	CHI.	
2).	Chronic	HCV	risk	factor	model	(Model	2)-	In	this	model,	we	have	included	the	demographic	
variables,	blood	transfusion,	number	of	CHI.		
3).	Chronic	HCV	Behavioral	Risk	Factor	and	Surveillance	System	(BRFSS)	model	(Model	3)-	
BRFSS	is	the	nation’s	premier	system	of	health-related	telephone	surveys	that	collect	state	data	
about	U.S.	residents	regarding	their	health-related	risk	behaviors,	chronic	health	conditions	and	
use	of	preventive	services	(www.cdc.gov/brfss/index.html).	In	this	model,	we	have	included	
only	variables	that	are	also	available	on	the	BRFSS.	This	includes	the	demographic	variables,	
alcohol	use	and	smoking	to	assess	the	associations	with	CHI.	In	the	future,	the	results	of	model	
will	be	critical	for	developing	a	prediction	model	to	estimate	state-level	prevalence	of	CHI.	
						The	C-statistic	(sometimes	called	the	‘concordance’	statistic	or	C-index)	is	a	measure	of	
goodness	of	fit	for	binary	outcomes	in	a	logistic	regression	model.	It	is	a	standard	measure	of	
the	predictive	accuracy	of	a	logistic	regression	model	(40).	It	is	equal	to	the	area	under	the	
Receiver	Operating	Characteristic	(ROC)	curve	and	ranges	from	0.5	to	1.	
• A	value	<	0.5	indicates	a	very	poor	model.	
• A	value	of	0.5	means	that	the	model	is	no	better	than	predicting	an	outcome	by	random	
chance.		
• Values	>	0.7	indicate	a	good	model.		
• Values	>	0.8	indicate	a	strong	model.	
• A	value	of	1	means	that	the	model	perfectly	predicts	those	group	members	who	will	
experience	a	certain	outcome	and	those	who	will	not.		
We	have	compared	the	c-statistics	between	the	three	models	in	this	study.	
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CHAPTER	FOUR	
RESULTS		
4.1	Estimated	Prevalence	of	HCV	RNA	
						The	estimated	number	of	HCV	RNA-positive	persons	among	of	age	20-59	years	in	birth	
cohorts	2003-2004,	2005-2006,	2007-2008,	2009-2020,	2011-2012,	2013-2014	were	2.56	
million	(95%	CI,	1.75-3.36),	2.19	million	(95%	CI,	1.23-3.13),	2.68	million	(95%	CI,	1.71-3.64),	
1.95	million	(95%	CI,	1.12-2.76),	2.08	million	(95%	CI,	0.95-3.19)	and	1.92	million	(95%	CI,	1.41-
2.43)	respectively	(Figure	2).	Figure	2	shows	that	estimated	number	of	CHI	population	has	
decreased	since	2008,	but	the	differences	were	not	statistically	significant.		
Figure		2:	Weighted	estimates	of	CHI	persons	of	age	20-59	y	from	2003-2014	
	
	
						
Drug	use,	smoking	and	alcohol	use	were	the	substance	abuse	risk	factors	for	CHI	in	this	study.	
Based	on	the	number	of	substance	abuse	risk	factors,	we	grouped	these	into	three	categories	
as	low	(0-1),	moderate	(2-4)	and	high	(5-7).	Next,	we	estimated	the	prevalence	of	chronic	HCV	
RNA-positive	persons	by	these	three	categories	(Figure	3).	Prevalence	of	CHI	increased	
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gradually	from	0.2%	at	low	to	1.1%	at	moderate	risk,	followed	by	a	sharp	increase	to	11.0	%	at	
high-risk	population.	
	
Figure	3:	Prevalence	of	chronic	HCV	by	number	of	substance	abuse	risk	factors,	2003-2014	
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4.2	Crude	associations	of	Demographic	and	Behavioral	Risk	Factors	of	persons	with	CHI	
						We	have	presented	descriptive	statistics	on	demographical	and	behavioral	risk	factors	of	
persons	with	CHI	by	bivariate	analyses	(Table	2).	Age,	race/ethnicity,	education,	marital	status,	
and	family	income	were	associated	with	HCV-RNA-positive	status.		
						Participants	of	age	40-59	years	had	a	CHI	prevalence	of	2.48%	and	more	likely	to	be	
infected,	whereas	CHI	prevalence	was	0.37	in	20-39	y	age	group.	Non-Hispanic	blacks	had	a	CHI	
prevalence	of	2.25%	when	compared	to	1.14%	in	other	races.	Male	participants	had	a	CHI	
prevalence	of	1.84%	when	compared	to	0.96%	in	females.	Participants	with	less	than	high	
school	education/GED	had	a	CHI	prevalence	of	2.26%	when	compared	to	1.11%	in	participants	
who	had	high	school	education	and	above.	Widowed/divorced/separated	participants	had	the	
highest	CHI	prevalence	of	2.75%	when	compared	to	never	married,	married/living	with	partner	
groups	who	had	a	CHI	prevalence	of	1.00%	and	1.20%	respectively.	Participants	who	were	at	<	
2.0	times	poverty	level	had	a	CHI	prevalence	of	2.15%	when	compared	to	0.76%	in	participants	
who	were	at	>	2.0	times	poverty	level.	
Table	2:	Demographic	Characteristics	by	CHI	status	in	participants	of	age	20-59	years,	NHANES	
2003-2014	
Variable	 Category	 Sample	Size	 HCV	RNA-
Positive	
%HCV	RNA-
positive	
Age,	years	 20-39	 10,696	 40	 0.37	
	 40-49	 5,309	 111	 2.09	
	 50-59	 4,649	 134	 2.88	
Race	 Non-Hispanic	black	 4397	 99	 2.25	
	 Other	races	 16,257	 186	 1.14	
Gender	 Male	 9,907	 182	 1.84	
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						Bivariate	analysis	of	behavioral	risk	factors	indicated	that	participants	who	smoked	had	a	
CHI	prevalence	of	2.76%	as	compared	to	0.33%	among	non-smokers.	Participants	who	
consumed	alcohol	had	a	CHI	prevalence	of	1.71%	and	more	likely	to	be	infected	when	
compared	to	non-consumers	of	alcohol	who	had	a	0.84%	CHI	prevalence.	Participants	who	had	
consumed	marijuana,	cocaine,	methamphetamine,	heroin	had	a	CHI	prevalence	of	2.23%,	
5.01%,	7.17%	and	18.16%	when	compared	to	the	CHI	prevalence	0.4%,	0.55%,	0.93%	and	0.94%	
among	non-consumers	of	marijuana,	cocaine,	methamphetamine	and	heroin	respectively.	IDU	
participants	had	a	CHI	prevalence	of	30.24%	while	non-injection	drug	users	were	0.71%	CHI	
prevalent.	Recipients	of	blood	transfusion	had	a	CHI	prevalence	of	2.47%	as	compared	to	1.19%	
in	participants	who	were	not	recipients	of	blood	transfusion.	Participants	who	had	>/=	10	
lifetime	sex-partners	had	a	CHI	prevalence	of	2.63%	as	compared	to	0.27%	and	0.82%	in	other	
	 Female	 10,747	 103	 0.96	
Education	 Less	than	high	
school	education	
4,787	 108	 2.26	
	 High	school	
education	and	
above	
15,851	 176	 1.11	
Marital	status	 Never	married	 5,007	 50	 1.00	
	 Widowed,	divorced,	
separated	
3,052	 84	 2.75	
	 Married,	living	with	
partner	
12,585	 151	 1.20	
Family	Income	 <	2.0	times	poverty	
level	
9,158	 197	 2.15	
	 >/=	2.0	times	
poverty	level	
10,044	 76	 0.76	
	 34	
groups.	Participants	in	high	substance	abuse	risk	factors	category	had	a	CHI	prevalence	of	
11.11%	as	compared	to	0.24%	and	1.12%	CHI	prevalence	in	participants	in	low	and	moderate	
categories	(Table	3).		
Table	3:	Behavioral	Risk	Factors	by	CHI	status	in	participants	of	age	20-59	years,	NHANES	
2003-2014			
Variable	 Category	 Sample	Size	 HCV	RNA-
Positive	
%HCV	RNA-
positive	
Ever	smoked	 Yes	 8,911	 246	 2.76	
	 No	 11,734	 39	 0.33	
Alcohol	 Yes	 7,708	 132	 1.71	
	 No	 9,239	 78	 0.84	
Evermarijuana	 Yes	 8,424	 188	 2.23	
	 No	 7,079	 28	 0.40	
Evercocaine	 Yes	 2,837	 142	 5.01	
	 No	 12,651	 70	 0.55	
Evermethamphetamine	 Yes	 1,130	 81	 7.17	
	 No	 14,359	 133	 0.93	
Everheroin	 Yes	 391	 71	 18.16	
	 No	 15,095	 142	 0.94	
Everinject	 Yes	 410	 124	 30.24	
	 No	 17,744	 126	 0.71	
Blood	transfusion	 Yes	 4,170	 103	 2.47	
	 No	 19,017	 227	 1.19	
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Lifetime	sex-partners	 0-1	 2,588	 7	 0.27	
	 2	to	9	 7,299	 60	 0.82	
	 >/=10	 5,066	 133	 2.63	
Substance	abuse	risk	
factors	
Low	(0-1)	 7,072	 17	 0.24	
	 Moderate	
(2,3,4)	
6,352	 71	 1.12	
	 High	(5,6,7)	 702	 78	 11.11	
4.3	Associations	between	risk	factors	and	CHI	adjusted	for	potential	confounders		
						In	this	study,	we	have	predicted	associations	between	risk	factors	and	CHI	using	three	
models	whose	results	are	described	below.		
1).	Model	1	-	For	adjusted	weighted	multivariate	logistic	regression	analysis,	demographic	
and	risk	factor	variables	were	adjusted	for	all	variables	in	the	model.	Simple	unadjusted	
logistic	regression	indicated	for	participants	of	age	20-59	years	found	that	age	40-59	
years,	male	sex,	non-Hispanic	black,	separated/divorced/widowed/living	separately,	less	
than	high	school/GED	education,	family	income	less	than	twice	the	poverty	level,	
smoking,	alcohol	consumption,	marijuana,	cocaine,	heroin	use,	use	of	injection	drugs,	
blood	transfusion	and	having	>/=	10	lifetime	sex-partners	were	significantly	associated	
with	CHI.		
								Adjusted	logistic	regression	analysis	for	participants	of	age	20-59	years	found	that	
participants	with	the	following	characteristics	had	significant	associations	with	CHI,	
indicating	they	had	higher	odds	of	an	HCV	infection	when	compared	to	their	respective	
referent	groups	(Table	4).		
1. Age	groups	40-49	y	and	50-59	y	had	an	odds	ratio	(OR)	of	7.9	(95%	CI,	3.8-16.2)	and	
8.0	(95%	CI,	3.5-18.2)	respectively	
2. Non-Hispanic	blacks	had	an	OR	of	2.4	(95%	CI,	1.3-4.1)	as	compared	to	the	referent	
group	
3. Less	than	high	school/GED	had	an	OR	of	2.6	(95%	CI,	1.5-4.8)	
4. Family	income	at	<	2.0	times	poverty	level	had	an	OR	of	3.5	(95%	CI,	1.9-6.6)	
5. Heroin	consumers	had	an	OR	of	2.3	(95%	CI,	1.1-4.6)	
6. IDU	had	an	OR	of	8.1	(95%	CI,	3.1-21)		
7. Blood	transfusion	had	an	OR	of	2.9	(95%	CI,	1.4-5.7)	
8. >/=	10	lifetime	sex-partners	had	an	OR	of	5.5	(95%	CI,	1.5-19.7)		
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Table	4:	Model	1	-	Unadjusted	and	adjusted	odds	ratios	for	the	risk	associated	with	CHI	in	
participants	of	age	20-59	years,	NHANES	2003	–	2014	(n	=	11,596).		
	
Characteristic	 Unadjusted	 Adjusted	
	 OR	 95%	CI	 OR	 95%	CI	
Age	at	interview	 	 	 	 	
20-39	y	 (ref)	 (ref)	 (ref)	 (ref)	
40-49	y	 5.8	 2.9-11.5	 7.9	 3.8-16.2	
50-59	y	 5.9	 3.0-11.9	 8.0	 3.5-18.2	
Sex	 	 	 	 	
Male	 2.8	 1.6-4.9	 2.3	 0.9-5.5	
Female	 (ref)	 (ref)	 (ref)	 (ref)	
Race/ethnicity	 	 	 	 	
Non-Hispanic	Black	 2.4	 1.5-3.8	 2.4	 1.3-4.1	
Other	races	 (ref)	 (ref)	 (ref)	 (ref)	
Marital	 	 	 	 	
Married,	living	with	partner	 (ref)	 (ref)	 (ref)	 (ref)	
Sep/Div/Wid/Liv	Sep	 2.7	 1.5-4.7	 1	 0.4-2.1	
Never	married	 1.2	 0.7-2.3	 1.2	 0.5-2.7	
Highest	education	level	 	 	 	 	
Less	than	high	school/GED	 4.6	 3.0-7.1	 2.6	 1.5-4.8	
High	school	or	more	 (ref)	 (ref)	 (ref)	 (ref)	
Family	income	 	 	 	 	
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<	2.0	times	poverty	level	 4.6	 2.8-7.8	 3.5	 1.9-6.6	
>=	2.0	times	poverty	level	 (ref)	 (ref)	 (ref)	 (ref)	
Smoking	 	 	 	 	
Yes	 6.7	 3.5-12.9	 1.9	 0.8-4.2	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Alcohol	Consumption	 	 	 	 	
Yes	 2.1	 1.3-3.3	 1.3	 0.7-2.3	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Marijuana	 	 	 	 	
Yes	 3.6	 2.0-6.6	 0.7	 0.3-1.9	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Cocaine	 	 	 	 	
Yes	 10.5	 6.3-17.6	 1.8	 0.9-3.7	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Heroin	 	 	 	 	
Yes	 28.7	 18.0-45.7	 2.3	 1.1-4.6	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Methamphetamine	 	 	 	 	
Yes	 12	 7.2-20.0	 1.9	 0.8-4.5	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Injection	drugs	 	 	 	 	
Yes	 46	 29.3-72	 8.1	 3.1-21	
No	 (ref)	 (ref)	 (ref)	 (ref)	
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Blood	transfusion	 	 	 	 	
Yes	 2.9	 1.7-5.0	 2.9	 1.4-5.7	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Lifetime	sex-partners	 	 	 	 	
0-1	 (ref)	 (ref)	 (ref)	 (ref)	
2-9	 4.4	 1.5-13	 2.8	 0.9-8.5	
>/=10	 22.4	 7.7-65	 5.5	 1.5-19.7	
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2).	Model	2-	For	adjusted	weighted	multivariate	logistic	regression	analysis,	number	of	
substance	abuse	risk	factors	were	adjusted	for	cohort,	age,	race,	gender,	education,	family	
income,	marital	status,	blood	transfusion	and	number	of	lifetime	sex-partners	(Table	5).	Simple	
unadjusted	and	adjusted	logistic	regression	indicated	that	having	>/=	2	risk	factors	were	
significantly	associated	with	CHI.	In	the	adjusted	analysis,	participants	in	moderate	and	high	
categories	had	an	OR	of	2.5	(95%	CI,	1.1-5.5	and	30.3	(95%	CI,	12.1-76)	respectively,	indicating	a	
significant	association	with	CHI	when	compared	to	the	referent	group.		
Table	5:	Model	2	-	Unadjusted	and	adjusted	odds	ratios	for	the	risk	associated	with	CHI	in	
participants	of	age	20-59	years,	NHANES	2003	–	2014	(n	=	11,596).	
	
	
	
	
	
	
	
	
	
Characteristic	 																		Unadjusted	 													Adjusted	
Number	of	Drugs,	Smoking	
and	alcohol	
OR	 95%	CI	 OR	 95%	CI	
Low	(0-1)	 (ref)	 (ref)	 (ref)	 (ref)	
Moderate	(2-4)	 4.5	 2.1-9.54	 2.5	 1.1-5.5	
High	(5-7)	 54.5	 25.2-117.8	 30.3	 12.1-76	
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3).	Model	3	-	For	adjusted	weighted	multivariate	logistic	regression	analysis,	demographic	and	
risk	factor	variables	were	adjusted	for	all	variables	in	the	model	(Table	6).	Simple	unadjusted	
logistic	regression	for	participants	of	age	20-59	years	indicated	that	20	–	59	years,	male	sex,	
non-Hispanic	black,	separated/divorced/widowed/living	separately,	having	less	than	high	
school/GED	education,	family	income	less	than	twice	the	poverty	level,	alcohol	consumption	
and	smoking	were	significantly	associated	with	CHI.		
In	the	adjusted	analysis,	participants	with	the	following	characteristics	had	significant	
associations	with	CHI	therefore	indicating	that	they	had	higher	odds	of	an	HCV	infection	when	
compared	to	their	respective	referent	groups.	
1. 	Age	groups	40-49	y	and	50-59	y	had	an	odds	ratio	(OR)	of	7.5	(95%	CI,	3.5-15.9)	and	8.7	
(95%	CI,	4.2-18).	
2. Males	had	an	OR	of	3.1	(95%	CI,	1.5-6.4)		
3. Non-Hispanic	blacks	had	an	OR	of	1.8	(95%	CI,	1.1-2.9)		
4. Less	than	high	school/GED	had	an	OR	of	2.2	(95%	CI,	1.3-3.8)		
5. Family	income	<	2.0	times	the	poverty	level	had	an	OR	of	3.7	(95%	CI,	2.0-6.8)		
6. Alcohol	consumers	had	an	OR	of	1.7	(95%	CI,	1.0-2.9)	and		
7. Smokers	had	an	OR	of	3.7	(95%	CI,	1.8-7.6)		
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Table	6:	Model	3	-	Unadjusted	and	adjusted	odds	ratios	for	the	risk	associated	with	CHI	in	
participants	of	age	20-59	years,	NHANES	2003	–	2014	(n	=	11,596).	
Characteristic	 											Unadjusted	 					Adjusted	
	 OR	 95%	CI	 OR	 95%	CI	
Age	at	interview	 	 	 	 	
20-39	y	 (ref)	 (ref)	 (ref)	 (ref)	
40-49	y	 5.8	 2.9-11.5	 7.5	 3.5-15.9	
50-59	y	 6	 3.0-11.9	 8.7	 4.2-18	
Sex	 	 	 	 	
Male	 2.8	 1.7-4.9	 3.1	 1.5-6.4	
Female	 (ref)	 (ref)	 (ref)	 (ref)	
Race/ethnicity	 	 	 	 	
Non-Hispanic	Black	 2.3	 1.5-3.8	 1.8	 1.1-2.9	
Other	races	 (ref)	 (ref)	 (ref)	 (ref)	
Marital	 	 	 	 	
Married,	living	with	
partner	
(ref)	 (ref)	 (ref)	 (ref)	
Sep/Div/Wid/Liv	Sep	 2.7	 1.5-4.7	 1.4	 0.7-2.8	
Never	married	 1.2	 0.7-2.3	 1.4	 0.7-2.9	
Highest	education	
level	
	 	 	
Less	than	high	
school/GED	
4.6	 3.0-7.1	 2.2	 1.3-3.8	
High	school	or	more	 (ref)	 (ref)	 (ref)	 (ref)	
Family	Income	 	 	 	 	
<2.0	times	poverty	
level	
4.6	 2.8-7.8	 3.7	 2.0-6.8	
>=	2.0	times	poverty	
level	
(ref)	 (ref)	 (ref)	 (ref)	
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4.4	C-statistic-	C-statistic	of	the	models	1,	2	and	3	were	0.94,	0.92	and	0.88	respectively	
indicating	that	all	three	models	were	strong	models	with	a	higher	predictive	accuracy	of	CHI	in	
persons	strongly	associated	with	respective	demographic	and	behavioral	risk	factor	variables	in	
the	models.		
	
	
	
	
	
	
	
	
	
	
	
	
	
Alcohol	
Consumption	
	 	 	
Yes	 2.1	 1.3-3.3	 1.7	 1.0-2.9	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Smoking	 	 	 	 	
Yes	 6.7	 3.5-12.9	 3.7	 1.8-7.6	
No	 (ref)	 (ref)	 (ref)	 (ref)	
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CHAPTER	FIVE	
DISCUSSION	AND	CONCLUSIONS	
DISCUSSION	
						The	primary	purpose	of	this	study	was	complex	examination	of	the	NHANES	datasets	from	
2003-2014	to	assess	combination	of	demographical	and	behavioral	risk	factors	associated	with	
CHI	in	the	general	U.S.	population.	The	NHANES	survey	provides	important	information	as	it	
comprises	the	nationally	representative	sample	of	the	US	non-institutionalized	population.	The	
standardization	of	its	methods	allows	for	consistent	and	good	quality	data	collection	(41).	This	
is	the	first	study	of	its	kind	to	use	a	complex	data	set	of	6	cohorts	from	2003	through	2014	for	
examination	of	all	possible	risk	factors	(demographical	+	behavioral)	significantly	associated	
with	CHI	in	the	adult	US	population	20-59	years	of	age	using	3	models.		
					As	of	2014,	we	estimated	1.93	million	CHI	persons	in	the	general	U.S.	population	of	age	20-
59	years	with	a	prevalence	of	0.7%	sampled	by	NHANES.	This	has	slightly	declined	since	2010	
based	on	Denniston	et	al	estimation	of	2.7	million	as	CHI	infected	persons	from	2003-2010	in	
the	general	U.S.	population	(4).	As	indicated	in	their	study,	our	analysis	also	suggests	that	
declining	prevalence	of	CHI	in	the	noninstitutionalized	U.S.	population	may	likely	be	because	of	
increasing	mortality	from	HCV-related	conditions	(42).	This	prevalence	is	an	underestimation	of	
the	true	CHI	population	in	the	US	because	NHANES	does	not	include	high-risk	populations	
including	the	incarcerated,	hemodialysis	patients,	the	homeless	and	people	living	on	Indian	
reservations,	all	active	military	and	U.S.	citizens	living	outside	the	U.S.A.		
						In	this	study,	substance	abuse	risk	factors	such	as	drug	use,	alcohol	consumption	and	
smoking	were	grouped	into	low	(0-1),	moderate	(2-4)	and	high	(5-7)	summary	risk	factor	score	
categories	based	on	the	number	of	risk	factors.	In	the	absence	of	categorization	of	the	
summary	risk	factor	scores,	fewer	number	of	CHI	observations	were	observed	in	each	summary	
risk	factor	score	that	resulted	in	wider	confidence	intervals.	Thus,	categorization	helped	to	
overcome	this	concern.	We	have	estimated	the	prevalence	of	CHI	in	these	categories	and	found	
a	linear	increase	in	CHI	prevalence	with	increasing	number	of	substance	abuse	risk	factors	
(Figure:	3)	with	a	maximum	of	11%	CHI	prevalence	in	persons	pf	the	high	category.	This	is	the	
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first	study	of	its	kind	to	estimate	the	CHI	prevalence	in	persons	associated	with	one	or	more	
substance	abuse	risk	factors.		
						Higher	prevalence	of	CHI	was	seen	in	participants	with	the	following	socio-demographic	
characteristics-	40-59	years,	non-Hispanic	black,	male	sex,	less	than	high	school	education,	
widowed/divorced/separated	and	family	income	less	than	2.0	times	poverty	level	when	
compared	to	their	respective	control	groups	(Table	2).	One	or	more	of	these	observations	were	
also	reported	in	earlier	studies	(4,	28,	41).	The	Centers	for	Disease	Control	and	Prevention	and	
US	Preventive	Services	Task	Force	have	recommended	1-time	HCV	screening	in	persons	born	
between	1945-1965	(43,	44)	which	corresponds	to	age	49-69	in	the	year	2014	and	account	for	
most	of	the	prevalent	HCV	cases.	Table	3	in	this	study	noticeably	shows	that	the	age	groups	40-
49	and	50-59	had	a	prevalence	of	2.09%	and	2.88%	respectively	with	a	total	prevalence	of	
4.97%	contributing	to	93%	of	the	infected	population	in	20-59	years	of	age.	Results	from	our	
study	supports	the	findings	from	earlier	studies	(4,	41).	
						Higher	prevalence	of	CHI	was	seen	in	participants	with	the	following	behavioral	risk	
characteristics-	smoking,	alcohol	consumption,	consumption	of	marijuana,	cocaine,	
methamphetamine,	heroin,	injection	drug	users,	blood	transfusion	recipients	prior	to	1992	and	
>/=10	life	time	sex-partners	when	compared	to	their	respective	referent	groups	(Table	3).	
Denniston		et	al	(4)	in	their	study	have	determined	higher	prevalence	of	CHI	in	participants	of	
age	60	and	older	who	had	received	blood	transfusion	before	1992,	in	injection	drug	users,	and	
with	20-49	life	time	sexual	partners	when	compared	to	their	respective	referent	groups.	Taylor	
et	al	(39)	have	indicated	higher	prevalence	of	CHI	in	participants	who	were	former	drinkers	and	
excessive	current	drinkers	when	compared	to	non-drinkers.	Results	from	these	studies	are	in	
line	with	some	of	the	observations	we	have	seen	in	our	study	although	our	study	is	unique	
because	we	have	estimated	CHI	prevalence	in	population	who	are	smokers,	consumers	of	
heroin,	cocaine	and	methamphetamine	that	have	not	been	determined	in	previous	studies.		
						Knowledge	of	risk	factors	for	CHI	is	important	for	several	reasons	not	limited	to	1).	
Identification	of	at-risk	populations	to	link	to	treatment	and	care	2).	Resource	allocation	for	
prevention	measures	and	3).	To	propose	policy	and	guidelines	for	control	and	prevention	of	
CHI.	This	study	is	the	largest	and	most	comprehensive	so	far	where	the	multivariate	models	
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have	included	the	most	established	confounders.	This	study	is	also	the	first	of	its	kind	to	have	
determined	the	risk	factors	associated	with	CHI	by	three	models.	As	reported	in	a	previous	
study	(4),	the	chronic	HCV	full	model	(Table	4)	elicited	that	age	40-59	years,	non-Hispanic	
blacks,	less	than	high	school/GED,	<	2.0	times	poverty	level	were	significantly	associated	with	
CHI.	Additionally,	the	chronic	HCV	full	model	has	also	established	significant	associations	of	
heroin	consumption,	blood	transfusion	and	>/=10	lifetime	sex-partners	with	CHI	that	have	not	
been	reported	earlier.	IDU	remains	the	strongest	risk	factor	for	CHI	as	reported	earlier	(4)	
however	in	the	earlier	study	IDU	was	combined	with	other	drugs	as	a	risk	factor.	For	IDU	
association	with	CHI,	Denniston	et	al	(4)	have	reported	an	OR	of	8.7	whereas	we	have	reported	
an	OR	of	8.1,	therefore	showing	that	in	both	the	studies	the	OR	in	the	multivariate	model	is	
similar.	Race,	low	socioeconomic	status	and	less	education	were	associated	with	CHI	because	
these	factors	are	often	associated	with	high-risk	behaviors	and	hence	higher	risk	of	infection.		
						Chronic	HCV	risk	factor	model	undoubtedly	shows	that	the	OR	increases	with	increasing	
number	of	risk	factors	in	a	person.	This	is	the	first	study	where	the	number	of	substance	abuse	
risk	factors	(alcohol	consumption,	smoking	and	drug	use)	were	categorized	into	low,	moderate	
and	high-risk	categories	to	determine	the	odds	of	being	positive	for	CHI	(Table	4).	This	data	will	
be	crucial	in	identification	of	the	positively	infected	population,	link	them	to	treatment,	and	
care	before	they	become	susceptible	to	secondary	conditions	such	as	hepatocarcinoma	and	
cirrhosis	thereby	reducing	the	HCV	burden	and	its	associated	healthcare	costs.	Missing	values	in	
the	druq	use	questions	in	NHANES	may	not	be	equally	distributed	between	the	different	socio-
economic	status	(SES)	groups,	which	can	lead	to	the	biases	in	prevalence	estimation	and/or	risk	
factor	estimation.	
						BRFSS	datasets	does	not	contain	questions	on	risk	factor	variables	such	as	drug	use	including	
IDU	and	number	of	lifetime	sex-partners.	We	carried	out	the	third	and	final	model	to	establish	a	
prediction	model	for	the	state	level	estimates	of	CHI	including	only	alcohol	and	smoking	risk	
factor	variables,	which	are	available	in	BRFSS.	In	the	absence	of	other	potential	confounders	
used	in	model	1,	alcohol	consumption	and	smoking	were	significantly	associated	with	CHI	
(Table	6).	The	assumption	that	all	states	have	the	national	level	prevalence	of	CHI	may	yield	
inaccurate	state-specific	estimates	because	risk	of	CHI	more	than	likely	varies	by	state.	
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Therefore,	model	3	is	important	because	it	may	be	duplicated	to	calculate	state	level	estimates	
such	as	BRFSS	datasets	and	to	determine	the	state	level	prevalence	of	CHI.		
						The	values	of	C-statistic	for	the	three	models	in	this	study	were	0.94,	0.92	and	0.88	
respectively.	Such	high	c-statistic	values	indicate	stronger	models	with	higher	predictive	
accuracy	of	CHI	in	persons	with	associated	demographic	and	risk	factor	variables	in	respective	
models.	Even	with	the	limited	number	of	risk	factors	modeled	after	the	BRFSS	datasets,	c-
statistic	is	0.88	indicating	good	prediction	of	the	model.	Thus,	our	data	can	serve	as	validation	
of	the	model	based	on	BRFSS	datasets.	
Our	study	comes	with	several	limitations	as	stated	below,	
1. We	did	not	include	participants	of	ages	>/=	60	years	due	to	the	time	and	resource	
limitations	for	conducting	this	thesis	study.	This	limits	us	from	comparing	the	prevalence	
estimates	and	associations	with	CHI	in	this	age	group	(minus	the	drug	questions	and	life-
time	sex-partner	questions	which	are	not	asked	for	this	population	by	NHANES)	to	the	
results	in	previously	published	studies	(4).		
2. Since	NHANES	does	not	ask	drug	and	lifetime	sex-partner	questions	in	adults	of	age	>/=	
60,	we	do	not	know	the	total	true	estimates	of	CHI	prevalence	and	risk	factor	
associations	in	adults	inclusive	>/=	60	years.	In	future,	it	will	be	useful	to	conduct	similar	
studies	in	the	baby	boomers’	cohort	who	are	49-69	years	of	age	in	2014	because	this	
cohort	by	itself	is	an	important	risk	factor	for	CHI.		
3. We	did	not	present	anti-HCV	data	in	this	study	due	to	the	time	and	resource	limitations	
in	performing	the	thesis	work.	National	level	anti-HCV	prevalence	estimates	and	its	risk	
factor	associations	will	enable	to	understand	the	larger	picture	of	the	CHI	such	as	the	
conversion	of	the	number	of	acute	HCV	cases	into	chronic	HCV	cases.		
4. 	As	mentioned	in	earlier	studies	(4,	29,	41),	results	from	NHANES	data	are	only	
applicable	to	the	non-institutionalized	U.S.	civilian	population,	which	underestimates	
the	true	prevalence	of	CHI	because	of	the	exclusion	of	incarcerated,	homeless	and	
institutionalized	population	in	the	datasets.	Results	from	this	thesis	cannot	be	
extrapolated	to	the	aforementioned	high-risk	groups	for	whom	the	prevalence	of	CHI	is	
likely	to	be	higher.		
	 48	
5. Questionnaire	data	is	relied	on	self-reporting	and	therefore	subject	to	recall	bias.	Use	of	
IDU	and	other	drugs,	having	>/=	10	lifetime	sex-partners	are	socially	stigmatized	
activities	which	may	result	in	participants	being	unwilling	to	admit	to	this	behavior	
resulting	in	an	underestimation	of	these	factors	in	CHI	prevalence	and	risk	factor	
associations.		
CONCLUSIONS	
						We	conclude	that	the	estimated	persons	infected	with	CHI	as	of	2014	is	approximately	2.2	
million	in	the	civilian	non-institutionalized	U.S	population	sampled	by	NHANES.	It	has	somewhat	
declined	since	2010	which	may	be	because	of	HCV	related	mortality,	however	the	true	
prevalence	estimates	of	CHI	will	be	significantly	higher	when	incarcerated,	homeless	and	other	
population	excluded	from	NHANES	are	included	in	the	analysis.	Injection	drug	use	continues	to	
be	the	strongest	risk	factor	for	CHI.	Persons	with	two	or	more	substance	abuse	risk	factors	have	
the	highest	odds	of	getting	CHI.	Results	from	this	study	will	be	critical	in	development	of	public	
health	policies	and	guidelines	for	the	identification	of	underappreciated	CHI	population	and	
linking	them	to	appropriate	treatment	and	care.		
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